

CITATION REPORT

List of articles citing

Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base

DOI: 10.1016/j.ijrobp.2014.01.001

International Journal of Radiation Oncology Biology Physics, 2014, 88, 1048-56.

Source: <https://exaly.com/paper-pdf/58680713/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
68	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014 , 8, 309-16	1.2	12
67	Outcomes of radical cystectomy in potential candidates for bladder preservation therapy. <i>Urology</i> , 2015 , 85, 869-75	1.6	15
66	How I treat bladder cancer in elderly patients. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 1-7	3.6	16
65	Preoperative imaging for staging bladder cancer. <i>Current Urology Reports</i> , 2015 , 16, 22	2.9	30
64	Targeting the VEGF pathway in metastatic bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 913-27	5.9	31
63	Trimodality therapy in bladder cancer: who, what, and when?. <i>Urologic Clinics of North America</i> , 2015 , 42, 169-80, vii	2.9	26
62	Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35	5.5	101
61	Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 387-96	7	62
60	Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 271-8	2.8	6
59	[Short version of the German S3 guideline for bladder cancer]. <i>Der Urologe</i> , 2016 , 55, 1173-87		10
58	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202 ¹		22
57	The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2016 , 34, 1561-1566	4	3
56	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 4.e11-7	2.8	9
55	Bladder Cancer. 2016 , 1096-1120.e6		0
54	Contemporary role of advanced imaging for bladder cancer staging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 124-33	2.8	18
53	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017 , 71, 952-960	10.2	153
52	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017 , 35, 1401-1407	4	26

51	Metastatic Bladder Cancer. 2017 , 177-198			1
50	Bladder Cancer. 2017 , 481-496			
49	In vivo fluorescence imaging of an orthotopic rat bladder tumor model indicates differential uptake of intravesically instilled near-infrared labeled 2-deoxyglucose analog by neoplastic urinary bladder tissues. 2017 ,			
48	Comparative analysis between radical cystectomy and trimodality therapy for clinical stage II bladder cancer [Experience from a tertiary referral center. <i>Urological Science</i> , 2017 ,	0.3		
47	Kurzform der S3-Leitlinie Harnblasenkarzinom. <i>Uro-News</i> , 2017 , 21, 32-42	0		
46	Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis. <i>Oncotarget</i> , 2017 , 8, 68996-69004	3.3	22	
45	Predictors of clinical-pathologic stage discrepancy in oral cavity squamous cell carcinoma: A National Cancer Database study. <i>Head and Neck</i> , 2018 , 40, 828-836	4.2	4	
44	Perioperative Preparation and Nutritional Considerations for Patients Undergoing Urinary Diversion. <i>Urologic Clinics of North America</i> , 2018 , 45, 11-17	2.9	5	
43	Bladder-Sparing Treatments. 2018 , 467-505			
42	Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2018 , 4, 720-724	5.1	14	
41	Predictors of Clinicopathologic Stage Discrepancy in Oropharyngeal Squamous Cell Carcinoma: A National Cancer Database Study. <i>Otolaryngology - Head and Neck Surgery</i> , 2018 , 158, 309-318	5.5	6	
40	Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. <i>Journal of Urology</i> , 2018 , 200, 996-1004	2.5	6	
39	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2019 , 125, 3155-3163	6.4	15	
38	Radiation oncology crossword: Genitourinary cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019 , 24, 281-283	1.5	2	
37	Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e209-e215	3.3	1	
36	Trimodality therapy for bladder cancer: modern management and future directions. <i>Current Opinion in Urology</i> , 2019 , 29, 210-215	2.8	10	
35	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019 , 75, 604-611	10.2	112	
34	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019 , 123, 947-958	5.6	8	

33	A delay 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 116-122	2.8	13
32	Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?. <i>European Urology Focus</i> , 2020 , 6, 617-619	5.1	0
31	The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. <i>Clinical Oncology</i> , 2020 , 32, 93-100	2.8	4
30	Carcinoma of the Bladder. 2020 , 1382-1400.e4		0
29	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020 , 77, 636-643	10.2	48
28	Timing of adjuvant chemotherapy and overall survival following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 75.e15-75.e22	2.8	3
27	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021 , 7, 1092-1099	5.1	1
26	Diagnostic Accuracy of Multiparametric MRI for Local Staging of Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Urology</i> , 2020 , 145, 22-29	1.6	4
25	Perioperative systemic chemo-immunotherapy for upper urinary tract urothelial carcinoma. <i>The Cochrane Library</i> , 2020 ,	5.2	78
24	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. <i>Current Oncology Reports</i> , 2020 , 22, 14	6.3	10
23	Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2020 , 154, 208-214	1.9	2
22	Can preoperative imaging characteristics predict pT3 bladder cancer following cystectomy?. <i>World Journal of Urology</i> , 2021 , 39, 1941-1945	4	
21	Clinical Versus Pathologic Laryngeal Cancer Staging and the Impact of Stage Change on Outcomes. <i>Laryngoscope</i> , 2021 , 131, 559-565	3.6	2
20	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 235.e15-235.e21	2.8	3
19	Trimodal Therapy. 2021 , 257-280		
18	MR-Guided Adaptive Radiotherapy for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 637591	5.3	10
17	Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study. <i>Cancer Medicine</i> , 2021 , 10, 3004-3012	4.8	0
16	Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer. <i>Acta Oncologica</i> , 2021 , 60, 794-802	3.2	0

15	Discrepancy between clinical and pathological T ₃ stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan. <i>International Journal of Urology</i> , 2021 , 28, 814-819	2.3	0
14	Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Endourology</i> , 2021 , 35, 1541-1547	2.7	0
13	Segmentation of the urothelium in optical coherence tomography images with dynamic contrast. <i>Journal of Biomedical Optics</i> , 2021 , 26,	3.5	1
12	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. <i>Bladder</i> , 2018 , 5, e34	2	1
11	A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis. <i>Oncotarget</i> , 2016 , 7, 61284-61294	3.3	21
10	Bimanual palpation for staging of bladder cancer-clinical use and its predictors. <i>Turkish Journal of Urology</i> , 2019 , 45, 22-26	1.3	0
9	Comparative analysis between radical cystectomy and trimodality therapy for clinical Stage II Bladder Cancer: Experience from a tertiary referral center. <i>Urological Science</i> , 2018 , 29, 25	0.3	
8	Computed-tomography based scoring system predicts outcome for clinical lymph node-positive patients undergoing radical cystectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022 , 48, 89-98	2	0
7	Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy. <i>Journal of Cancer Research and Clinical Oncology</i> ,	4.9	
6	The rate of prostatic involvement in men treated with radical cystectomy for muscle invasive bladder cancer. <i>Practical Radiation Oncology</i> , 2022 ,	2.8	
5	Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy. <i>International Journal of Urology</i> ,	2.3	0
4	Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy. Volume 14, 281-290		
3	Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy. 12,		0
2	Higher Expression of Annexin A2 in Metastatic Bladder Urothelial Carcinoma Promotes Migration and Invasion. 2022 , 14, 5664		0
1	Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations. 2023 , 15, 1323		0